Last reviewed · How we verify
GLPG2222 multiple doses
At a glance
| Generic name | GLPG2222 multiple doses |
|---|---|
| Sponsor | Galapagos NV |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study Looking at the Safety, Tolerability and Efficacy of the Combination of the Study Drugs GLPG2451 and GLPG2222 With or Without GLPG2737 in Patients With Cystic Fibrosis. (PHASE1)
- A Study to Evaluate Multiple Doses of GLPG2222 in Adult Subjects With Cystic Fibrosis (PHASE2)
- A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG3067 in Healthy Subjects. (PHASE1)
- A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG2451 in Healthy Male Subjects (PHASE1)
- A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG2451 in Healthy Female Subjects (PHASE1)
- First-in-Human Single and Multiple Dose of GLPG2222 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GLPG2222 multiple doses CI brief — competitive landscape report
- GLPG2222 multiple doses updates RSS · CI watch RSS
- Galapagos NV portfolio CI